IL297240A - Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof - Google Patents

Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Info

Publication number
IL297240A
IL297240A IL297240A IL29724022A IL297240A IL 297240 A IL297240 A IL 297240A IL 297240 A IL297240 A IL 297240A IL 29724022 A IL29724022 A IL 29724022A IL 297240 A IL297240 A IL 297240A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
lazertinib
tablet
mesylate
pharmaceutical formulation
Prior art date
Application number
IL297240A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL297240A publication Critical patent/IL297240A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL297240A 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof IL297240A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US202063014277P 2020-04-23 2020-04-23
PCT/IB2021/053035 WO2021209893A1 (en) 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Publications (1)

Publication Number Publication Date
IL297240A true IL297240A (en) 2022-12-01

Family

ID=75562794

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297240A IL297240A (en) 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Country Status (12)

Country Link
US (2) US12138351B2 (https=)
EP (1) EP4135669A1 (https=)
JP (2) JP7787824B2 (https=)
KR (1) KR20230002656A (https=)
CN (1) CN115484937A (https=)
AU (2) AU2021257662B2 (https=)
CA (1) CA3180184A1 (https=)
IL (1) IL297240A (https=)
MX (1) MX2022012898A (https=)
PH (1) PH12022552454A1 (https=)
UY (1) UY39171A (https=)
WO (1) WO2021209893A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2022253261A1 (zh) * 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US6399591B1 (en) 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
US7998505B2 (en) 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
ES2713330T3 (es) 2009-12-11 2019-05-21 Sumitomo Dainippon Pharma Co Ltd Comprimido recubierto en seco que se desintegra oralmente
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
WO2015006752A1 (en) * 2013-07-12 2015-01-15 The Regents Of The University Of California Combination therapies for malaria
SMT202100205T1 (it) 2013-12-12 2021-07-12 Almirall Sa Composizioni farmaceutiche comprendenti dimetil fumarato
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
HUE054848T2 (hu) 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
SG11201808626WA (en) 2016-04-07 2018-10-30 Chemocentryx Inc Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11198731B2 (en) * 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MY201038A (en) 2017-07-28 2024-01-31 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
WO2019022486A1 (en) 2017-07-28 2019-01-31 Yuhan Corporation NOVEL INTERMEDIATES USEFUL FOR SYNTHESIZING AMINOPYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND PROCESS FOR PREPARING AMINOPYRIMIDINE DERIVATIVES THEREWITH
SG11201913517UA (en) 2017-07-28 2020-02-27 Yuhan Corp Improved process for preparing aminopyrimidine derivatives
CN110580014B (zh) * 2018-06-11 2021-03-30 北京京东尚科信息技术有限公司 用于控制自动导引运输车的方法、装置和系统
CN113164971A (zh) 2018-07-20 2021-07-23 英默里斯美国公司 从铸造用砂废弃物中回收砂、膨润土和有机物
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US12576033B2 (en) 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
WO2020211915A1 (en) 2019-04-17 2020-10-22 Nordiccan A/S Fast disintegrating cannabinoid tablets
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN119909073A (zh) 2019-07-31 2025-05-02 豪夫迈·罗氏有限公司 新型药物制剂

Also Published As

Publication number Publication date
JP2025179094A (ja) 2025-12-09
AU2021257662B2 (en) 2025-06-12
PH12022552454A1 (en) 2024-02-05
MX2022012898A (es) 2023-01-24
CN115484937A (zh) 2022-12-16
WO2021209893A1 (en) 2021-10-21
JP7787824B2 (ja) 2025-12-17
AU2021257662A1 (en) 2022-12-15
US20210322323A1 (en) 2021-10-21
BR112022020609A2 (pt) 2022-11-29
CA3180184A1 (en) 2021-10-21
AU2025203347A1 (en) 2025-05-29
WO2021209893A8 (en) 2022-10-13
KR20230002656A (ko) 2023-01-05
TW202207940A (zh) 2022-03-01
US20250177311A1 (en) 2025-06-05
JP2023522634A (ja) 2023-05-31
US12138351B2 (en) 2024-11-12
UY39171A (es) 2021-10-29
EP4135669A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
IL297240A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
KR100440553B1 (ko) 서방성 제제
IL282163B1 (en) A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or a salt thereof
NZ583269A (en) Novel forms of cddo methyl ester also known as methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28 oate
RU2322970C2 (ru) Фармацевтические композиции, включающие коллоидную двуокись кремния
IL305435A (en) Psilocybin compositions, methods of making and methods of using the same
IL296014A (en) Tablets containing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
IL261745B2 (en) Granular formulation of 5-methyl-1-phenyl-2(h1)-pyridone and method for its preparation
IL293821A (en) Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
IL224189A (en) C-met modulator pharmaceutical compositions
IL259493A (en) Solid dispersions containing sgc actuator
IL303352B1 (en) Immediate-release tablets containing a drug and processes for forming the tablets
IL297642A (en) Methods for using t-type calcium channel modulators
IL294959A (en) Methods of treatment for alpha-1 antitrypsin deficiency
IL296352A (en) Method for treatment of covid-19-associated conditions
IL297840A (en) Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
IL298872A (en) Dosage forms of eclobrutinib maleate
IL322310A (en) Methods for treating multiple sclerosis complex
EA048109B1 (ru) Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его фармацевтически приемлемую соль, гидрат или сольват
BR112022020609B1 (pt) Composição e formulação farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo e seus usos
HK40085907A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US20240216352A1 (en) Lpa1 antagonists for treating interstitial lung disease
TWI921305B (zh) Rbp4抑制劑之調配物及使用方法
IL295992A (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
HK40105586A (zh) 包含依那格列净的药物组合物